BIODESIX, INC. Revenue
BIODESIX, INC. (BDSX) reported Revenue of $26.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-05
- BIODESIX, INC. revenues for the quarter ending 2026-06-30 was $26.86M, a 34.18% increase year-over-year.
- BIODESIX, INC. revenues for the quarter ending 2026-03-31 was $25.55M, a 42.30% increase year-over-year.
- BIODESIX, INC. revenues for the quarter ending 2025-12-31 was $28.75M, a 40.76% increase year-over-year.
- BIODESIX, INC. revenues for the quarter ending 2025-09-30 was $21.77M, a 19.93% increase year-over-year.
- BIODESIX, INC. revenues for fiscal 2025 was $88.50M, a 24.08% increase from fiscal 2024.
- BIODESIX, INC. revenues for fiscal 2024 was $71.32M, a 45.30% increase from fiscal 2023.
- BIODESIX, INC. revenues for fiscal 2023 was $49.09M, a 28.46% increase from fiscal 2022.
- BIODESIX, INC. revenues for fiscal 2022 was $38.21M, a 29.89% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.86M 10-Q · filed 2026-08-05 | $52.42M 10-Q · filed 2026-08-05 | $81.17M derived: sum of 3 quarters · filed 2026-08-05 | $102.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $25.55M 10-Q · filed 2026-05-04 | $54.31M derived: sum of 2 quarters · filed 2026-05-04 | $76.08M derived: sum of 3 quarters · filed 2026-05-04 | $96.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $28.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.52M derived: sum of 2 quarters · filed 2026-02-26 | $70.54M derived: sum of 3 quarters · filed 2026-08-05 | $88.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $21.77M 10-Q · filed 2025-11-03 | $41.79M derived: sum of 2 quarters · filed 2026-08-05 | $59.74M 10-Q · filed 2025-11-03 | $80.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $20.02M 10-Q · filed 2026-08-05 | $37.98M 10-Q · filed 2026-08-05 | $58.41M derived: sum of 3 quarters · filed 2026-08-05 | $76.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $17.96M 10-Q · filed 2026-05-04 | $38.39M derived: sum of 2 quarters · filed 2026-05-04 | $56.54M derived: sum of 3 quarters · filed 2026-05-04 | $74.46M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $20.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.58M derived: sum of 2 quarters · filed 2026-02-26 | $56.51M derived: sum of 3 quarters · filed 2026-02-26 | $71.32M 10-K · filed 2026-02-26 |
| 2024-09-30 | $18.15M 10-Q · filed 2025-11-03 | $36.08M derived: sum of 2 quarters · filed 2025-11-03 | $50.89M 10-Q · filed 2025-11-03 | $65.56M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $17.93M 10-Q · filed 2025-08-07 | $32.74M 10-Q · filed 2025-08-07 | $47.41M derived: sum of 3 quarters · filed 2025-08-07 | $60.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.82M 10-Q · filed 2025-05-13 | $29.49M derived: sum of 2 quarters · filed 2025-05-13 | $42.98M derived: sum of 3 quarters · filed 2025-05-13 | $54.85M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $28.16M derived: sum of 2 quarters · filed 2025-03-03 | $40.03M derived: sum of 3 quarters · filed 2025-03-03 | $49.09M 10-K · filed 2025-03-03 |
| 2023-09-30 | $13.49M 10-Q · filed 2024-11-01 | $25.36M derived: sum of 2 quarters · filed 2024-11-01 | $34.42M 10-Q · filed 2024-11-01 | $44.03M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $11.87M 10-Q · filed 2024-08-07 | $20.93M 10-Q · filed 2024-08-07 | $30.54M derived: sum of 3 quarters · filed 2024-08-07 | $41.64M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $9.06M 10-Q · filed 2024-05-08 | $18.66M derived: sum of 2 quarters · filed 2024-05-08 | $29.77M derived: sum of 3 quarters · filed 2024-05-08 | $40.72M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $20.71M derived: sum of 2 quarters · filed 2024-03-01 | $31.66M derived: sum of 3 quarters · filed 2024-03-01 | $38.21M 10-K · filed 2024-03-01 |
| 2022-09-30 | $11.11M 10-Q · filed 2023-11-07 | $22.06M derived: sum of 2 quarters · filed 2023-11-07 | $28.61M 10-Q · filed 2023-11-07 | $35.83M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $10.95M 10-Q · filed 2023-08-07 | $17.50M 10-Q · filed 2023-08-07 | $24.72M derived: sum of 3 quarters · filed 2023-08-07 | $31.25M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $6.55M 10-Q · filed 2023-05-11 | $13.77M derived: sum of 2 quarters · filed 2023-05-11 | $20.30M derived: sum of 3 quarters · filed 2023-05-11 | $32.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $13.76M derived: sum of 2 quarters · filed 2023-03-06 | $25.64M derived: sum of 3 quarters · filed 2023-03-06 | $54.51M 10-K · filed 2023-03-06 |
| 2021-09-30 | $6.53M 10-Q · filed 2022-11-03 | $18.42M derived: sum of 2 quarters · filed 2022-11-03 | $47.28M 10-Q · filed 2022-11-03 | $74.31M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $11.88M 10-Q · filed 2022-08-04 | $40.75M 10-Q · filed 2022-08-04 | $67.78M derived: sum of 3 quarters · filed 2022-08-04 | $76.97M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $28.87M 10-Q · filed 2022-05-11 | $55.90M derived: sum of 2 quarters · filed 2022-05-11 | $65.09M derived: sum of 3 quarters · filed 2022-05-11 | $69.33M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $27.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $36.22M derived: sum of 2 quarters · filed 2022-03-14 | $40.46M derived: sum of 3 quarters · filed 2022-03-14 | $45.56M 10-K · filed 2022-03-14 |
| 2020-09-30 | $9.19M 10-Q · filed 2021-11-15 | $13.43M derived: sum of 2 quarters · filed 2021-11-15 | $18.53M 10-Q · filed 2021-11-15 | $26.80M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $4.24M 10-Q · filed 2021-08-10 | $9.34M 10-Q · filed 2021-08-10 | $17.61M derived: sum of 3 quarters · filed 2021-08-10 | $21.55M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $5.10M 10-Q · filed 2021-05-11 | $13.37M derived: sum of 2 quarters · filed 2021-05-11 | $17.31M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $12.21M derived: sum of 2 quarters · filed 2021-03-16 | $24.55M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $3.94M 10-Q · filed 2020-12-10 | $16.28M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |